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BACKGROUND: Tumour necrosis reflects the presence of hypoxia, which can be indicative of an aggressive tumour phenotype. The aim
of this study was to investigate whether histological necrosis is a useful predictor of outcome in patients with pancreatic ductal
carcinoma (PDC).
METHODS: We reviewed histopathological findings in 348 cases of PDC in comparison with clinicopathological information.
We counted small necrotic foci (micronecrosis) as necrosis, in addition to massive necrosis that had been only defined as necrosis in
previous studies. The reproducibility of identifying histological parameters was tested by asking five independent observers to blindly
review 51 examples of PDC.
RESULTS: Both micronecrosis and massive necrosis corresponded to hypoxic foci expressing carbonic anhydrase IX detected by
immunohistochemistry. Multivariate survival analysis showed that histological necrosis was an independent predictor of poor
outcome in terms of both disease-free survival (DFS) and disease-specific survival (DSS) of PDC patients. In addition, metastatic
status, and lymphatic, venous, and intrapancreatic neural invasion were independent prognostic factors for shorter DFS and
metastatic status, margin status, lymphatic invasion, and intrapancreatic neural invasion were independent prognostic factors for DSS.
The interobserver reproducibility of necrosis identification among the five independent observers was ‘almost perfect’ (k-value
of 0.87).
CONCLUSION: Histological necrosis is a simple, accurate, and reproducible predictor of postoperative outcome in PDC patients.
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Pancreatic cancer (pancreatic ductal carcinoma (PDC)) is the
fourth and fifth leading cause of cancer-related death in the United
States and Japan, respectively (Center for Cancer Control and
Information Services and National Cancer Center, 2009; Jemal
et al, 2009). Because of its aggressive growth and early metastatic
dissemination, the overall 5-year survival rate for patients with
pancreatic cancer is 3–5%, and that of patients treated by curative
resection is 15–25% (Klo ¨ppel et al, 2000; Lim et al, 2003; Hruban
et al, 2007; Jemal et al, 2009). The mortality rate has not shown any
obvious improvement for decades. The development of predictive
biomarkers to assist the selection of patient subsets is useful for
studies aimed at reducing the mortality of PDC patients, especially
in phase clinical studies evaluating various therapeutic approaches
(Philip et al, 2009).
Several histopathological parameters such as tumour size (Yeo
et al, 1995; Sohn et al, 2000; Lim et al, 2003; Shimada et al, 2006),
tumour histological grade (Luttges et al, 2000; Adsay et al, 2005),
lymph nodal metastasis (Trede et al, 1990; Lim et al, 2003;
Schnelldorfer et al, 2008), and lymphatic, venous (Luttges et al,
2000; Takai et al, 2003), and neural invasion (Mitsunaga et al, 2005,
2007) have been proposed as hallmarks predictive of postoperative
outcome in patients with PDC. Stage is the most important
prognosticator (Klo ¨ppel et al, 2000; Hruban et al, 2007), although
majority of resectable cases were classified into advanced stage,
stage IIB of the International Union Against Cancer (UICC)
tumour–node–metastasis (TNM) classification and were not able
to be stratified more precisely. Histopathological evaluation of
PDC can be performed using routine diagnostic techniques in
pathology departments without any additional equipment or
special expertise. The predictive values of the above mentioned
parameters are sometimes controversial and complex, and some
have problems related to interobserver reproducibility. To avoid
these pitfalls and to stratify PDCs in a distinct and objective
manner, molecular or genetic markers have been developed,
although these often require special equipment or expertise and
cannot usually be performed on a routine basis. Therefore,
simpler, more reproducible, and easily assessable histopathological
predictors are needed.
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sHypoxia is a common feature of human cancers, which induces
a transcription programme mediated mainly by hypoxia-inducible
factor-1a (HIF-1a) that promotes aggressive tumour phenotype
(Harris, 2002; Vaupel and Mayer, 2007; Bristow and Hill, 2008).
It is a prognostic indicator in many solid tumours (Vaupel and
Mayer, 2007), and is often detected by examining the expression
of carbonic anhydrase IX (CAIX) (Chia et al, 2001), which is a
regulator of cellular pH and its expression is induced by HIF-1a
(Harris, 2002; Bristow and Hill, 2008). Intratumoural hypoxia is
reflected histologically by the presence of necrosis, which has also
been reported to be a prognostic factor in patients with breast
(Gilchrist et al, 1993) and bladder (Ord et al, 2007) cancers.
Hypoxia is evident in PDCs, in which expression of HIF-1a and
CAIX has been detected in 60–70% and 78% of cases, respectively
(Kitada et al, 2003; Couvelard et al, 2005; Sun et al, 2007), whereas
histological necrosis has been found in only 30–40% of PDCs in
previous studies (Couvelard et al, 2005; Mitsunaga et al, 2005).
Neither large-scale study nor multivariate survival study has
been performed to evaluate prognostic value of hypoxia in PDC
patients.
In this study, we found that necrotic areas were present in more
than 60% of PDCs when small necrotic foci were taken into
account. We also found that CAIX were expressed in and around
these necrotic lesions, indicating that these areas were in a
condition of hypoxia. Therefore, detection of necrosis using
our definition may offer a chance of stratifying PDC patients for
tissue hypoxia more accurately. In this study, with the aim of
investigating whether histologically evident necrosis is useful for
prediction of patient outcome among various histopathological
parameters, and we reviewed histopathological findings in 348
cases of PDC in comparison with clinicopathological information.
MATERIALS AND METHODS
Study population
This study was approved by the Ethics Committee of the National
Cancer Center, Japan. Clinical and pathological data were obtained
through a detailed retrospective review of the medical records of
all 348 patients with ductal carcinoma of the pancreas that had
undergone initial surgical resection between 1990 and 2005 at the
National Cancer Center Hospital. None of the patients had received
any previous therapy. All patients received standard therapy
appropriate for their clinical stages. The operative procedures
included 228 pancreatoduodenectomies or pylorus-preserving
pancreatoduodenectomies, 104 distal pancreatectomies, and
16 total pancreatectomies. Along with tumour extension, lympha-
denectomy was performed at the hepatoduodenal ligament and
around the abdominal aorta. All the patients included in this study
underwent macroscopic curative resection, which was defined as
the macroscopic removal of all gross tumours without liver
metastases, macroscopic peritoneal dissemination, bulky lymph
node involvement, or apparent tumour invasion around the
common hepatic or superior mesenteric arteries after routine
examination using intraoperative ultrasonography. All of the cases
were conventional ductal carcinomas and adenocarcinomas origi-
nating in intraductal papillary mucinous neoplasms or mucinous
cystic neoplasms were excluded. Secondary tumours and post-
neoadjuvant cases were also excluded. The clinicopathological
characters of the patients were summarized in Table 1. All M1
patients had nodal metastasis around the abdominal aorta, without
any other form of metastasis. Males accounted for 206 patients
and females for 142; the mean patient age was 62.9 years (range,
27–87 years). Every patient was followed up in the outpatient
clinic every 1–3 month during the first postoperative year,
and every 6–12 months thereafter. Patients underwent physical
examination, laboratory tests, chest radiography, abdominal
computed tomography, and/or ultrasonography, unless there was
a confirmed relapse. The tumour markers carcinoembryonic
antigen and carbohydrate antigen 19-9 were also measured until
relapse. Recurrence was suspected when a new local or distant
metastatic lesion was found on serial images and an increase in
tumour marker levels was recognised. When progression of the
disease was confirmed by repeated imaging studies, the date of the
first suspicious radiologic finding was used as the date of initial
disease recurrence. The median follow-up period after surgery
was 17.9 (1.3–210) months for the patients overall: 69 patients
(19.8%) were alive at the census date (June 2009), 239 (68.7%) died
because of pancreatic cancer, and 40 (11.5%) died of other causes.
Postresection adjuvant therapy information was available for 327
patients, of whom 19 received chemotherapy and radiotherapy, 134
received chemotherapy only, 2 received radiotherapy only, and 172
did not receive any additional therapy.
Pathological examination
All of the ductal carcinomas were pathologically reexamined and
were classified according to the World Health Organisation
classification (Klo ¨ppel et al, 2000), UICC TNM classification
(Wittekind et al, 2005), and the Classification of Pancreatic
Carcinoma of the Japan Pancreas Society (JPS) (Japan Pancreas
Society, 2003). Surgically resected specimens were fixed in 10%
formalin and cut into serial 5-mm-thick slices, horizontally in the
pancreas head, and sagittally in the pancreas body and tail. All the
sections were stained with hematoxylin and eosin for pathological
examination. The following histopathological variables were
evaluated according to the classification of JPS: tumour histolo-
gical grade, nerve plexus invasion, and lymphatic, venous, and
intrapancreatic neural invasion.
Tumour necrosis in PDCs was reported previously (Couvelard
et al, 2005; Mitsunaga et al, 2005), having been defined as
‘confluent cell death in invasive areas of primary cancer, visible at
an objective lens magnification of  40 (Mitsunaga et al, 2005),
which is the same to the definition having been mentioned in
breast cancer. Tumour histology often varies among the organs in
which tumours develop. We noticed that small areas of necrosis
were evident in PDCs, wherein gland formation by cancer cells
was ruptured, usually in association with neutrophil infiltration.
We refer to this hereafter as micronecrosis, and to the former
as massive necrosis. As sometimes it is difficult to differentiate
necrotic lesions into either of these two patterns, we combined
these two types of lesions solely as ‘necrosis’. The definition of
histological necrosis is as follows. Necrosis occurs in cancer tissue
regardless of its extent, and is usually found in both cancer cells
and cancer stroma (Figure 1). When coagulation necrosis is
extensively developed (massive necrosis), it corresponds to what
was referred to as necrosis previously (Couvelard et al, 2005;
Mitsunaga et al, 2005). Smaller areas of necrosis (micronecrosis)
often recognised adjacent to ruptured cancer-forming tubules is
almost always accompanied by neutrophil infiltration (Figure 1).
Interobserver reproducibility in identifying histological
characteristics
To test the reproducibility of identification of histological
characteristics, five independent observers (SS, HT, MY, KY,
and TK) were asked to review 51 examples of IDC that were
consecutive cases surgically resected between 1997 and 2000. One
slide was selected from each of the 51 cases. This slide was one of
the slides containing the maximum cut section of the tumour. The
complete set of slides from the 51 cases was sent to the five
independent observers, all of whom are general surgical patho-
logists with no specific expertise in the pancreas, and who
encounter pancreas specimens rarely. One observer (HT) specia-
lises in breast and female genitourinary pathology and one (SS) in
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sgastrointestinal tract pathology. These observers were provided
with the definition of ‘histological necrosis’ according to Figure 1
and with the definitions for lymphatic, venous, and neural
invasion stated in the classification of JPS (Japan Pancreas Society,
2003). They were asked to assess the presence of histological
necrosis and each of the grades of lymphatic, venous, and neural
invasion evident within each of the provided slides. These
observers were blind to the identity of the original reviewers or
those of each other. They were also not provided with any clinical
information on the outcome of the patients.
Immunohistochemical analysis
Immunohistochemistry was performed on formalin-fixed, paraf-
fin-embedded tissue sections as described previously (Takahashi
et al, 2007), using antibodies against CAIX (M75, 1:200)
(Pastorekova et al, 1992; Zavada et al, 2000) and HIF-1a (54,
1:500, BD Transduction Laboratories, Franklin Lakes, NJ,
USA). Avidin–biotin complex method and CSA system (DAKO,
Glostrup, Denmark) were used for these immunohistochemistry,
respectively. The sections were autoclaved in the buffer (pH 9.0,
Nichirei Biosciences, Tokyo, Japan) for antigen retrieval. For
immunohistochemical examination of CAIX in PDCs, we used
sections of representative blocks from 203 cases of PDC. Carbonic
anhydrase IX is expressed always in the crypt enterocytes of
the duodenum and sometimes in normal epithelial cells of the
pancreatic duct and pancreatic intraepithelial neoplasm. These
cells were used as the positive control for CAIX immunohisto-
chemistry. Immunohistochemistry was performed without pri-
mary antibody for negative control. When more than 20% of
cancer cells in the specimen expressed CAIX, the case was judged
as positive for CAIX in cancer cells. When there were any stromal
cells expressing CAIX in cancer tissue, the case was judged as
presence of stromal cells expressing CAIX.
Statistical analysis
Comparisons of qualitative variables were performed using the
w
2 test or Fisher’s exact test. One-way analysis of variance was used
to compare the means of three or more groups. The postoperative
disease-free survival (DFS) and disease-specific survival (DSS)
rates were calculated by the Kaplan–Meier method. Univariate
analysis was performed for prognostic factors using the log-rank
test. The factors found to be predictive by univariate analysis were
subjected to multivariate analysis using the Cox proportional
hazards model (backward elimination method). Interobserver
Table 1 Relationship between clinicopathological characteristics and
histological necrosis
Necrosis
Characteristics No. of patients Presence Absence P
Age, years
o60 123 75 48
X60 225 148 77 0.414
Sex
Male 206 143 63
Female 142 80 62 0.017
Localisation
Pancreas head 228 147 81
Pancreas body or tail 109 70 39 1.000
Size (mm)
o30 83 42 41
X30 265 181 84 0.004
Pathologic tumour status
T1 6 1 5
T2 3 3 0
T3 339 219 120
T4 0 0 0 0.023
a
Pathologic node status
N0 64 33 31
N1 284 190 94 0.030
Pathologic metastasis status
M0 310 193 117
M1 38 30 8 0.049
Stage
IA 3 0 3
IB 2 2 0
IIA 59 31 28
IIB 246 160 86
III 0 0 0
IV 38 30 8 0.009
a
Tumour histological grade
b
W/D 90 41 49
M/D 181 122 59
P/D 77 60 17 o0.0001
a
Tumour margin status
Negative 249 166 82
Positive 100 57 43 0.085
Nerve plexus invasion
b
Absence 112 65 47
Presence 236 158 78 0.120
Lymphatic invasion
b
0, 1 102 58 44
2, 3 246 165 81 0.086
Venous invasion
b
0, 1 124 63 61
2, 3 224 160 64 0.0002
Intrapancreatic neural invasion
b
0, 1 141 86 55
2, 3 207 137 70 0.363
Recurrent site
c
Local 54 39 15
Distant sites 198 134 64 0.620
Table 1 (Continued)
Necrosis
Characteristics No. of patients Presence Absence P
Expression of CAIX in cancer cells
d
Absence 114 69 45
Presence 89 63 26 0.143
Expression of CAIX in stromal cells
d
Absence 74 31 43
Presence 129 101 28 o0.0001
Total 348 223 125
Abbreviations: CAIX¼carbonic anhydrase IX; M/D¼moderately differentiated
adenocarcinoma; P/D¼poorly differentaited adenocarcinoma; W/D¼well-differ-
entiated adenocarcinoma.
aComparisons of qualitative variables are performed using
the w
2 test, and otherwise by Fisher’s exact test.
bClassified according to the
classification of pancreatic carcinoma of Japan Pancreas Society.
cNumber of patients
with tumour recurrence was 252.
dNumber of patients used in the immunohisto-
chemical analysis was 203. Statistically significant in bold values.
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sagreement (reproducibility) was tested by obtaining the k-scores
(Fleiss, 1971; Landis and Koch, 1977). Differences at Po0.05
were considered statistically significant. Statistical analyses were
performed with StatView-J 5.0 software (Abacus Concepts,
Berkeley, CA, USA).
RESULTS
Correspondence of both massive necrosis and
micronecrosis with hypoxic foci
Immunohistochemical analysis revealed that CAIX was expressed
in cancer cells or stromal cells within or around areas of both
massive necrosis and micronecrosis (Figure 2).
Prognostic significance of the presence of hypoxic foci
detected by expression of CAIX in cancer stromal cells
Survival analysis showed that the presence of hypoxic foci with
expression of CAIX in stromal cells in cancer tissue was closely
associated with shorter DFS (P¼0.004) and DSS (P¼0.003)
(Figure 3). The presence of cancer cells expressing CAIX was also
associated with shorter survival rates (Figure 3), although its
occasional expression in cancer cells forming well-differentiated
glands distant from necrotic areas probably indicated a cellular
phenotype similar to that of normal ductal epithelial cells, and was
unrelated to hypoxia. Then we used expression of CAIX in cancer
stromal cells as hypoxic marker in this study. Multivariate Cox
regression analysis revealed that the presence of hypoxic foci was
an independent predictor of shorter DFS (P¼0.005) and DSS
(P¼0.011) (Supplementary Table 1). The presence of necrosis was
significantly correlated with the presence of hypoxic foci (Table 1).
More CAIX-expressing cells were found in larger areas of necrosis.
Histopathological evaluation of PDC
Table 1 lists the clinicopathological features of patients with PDC.
When correlations with these clinicopathological features were
analyzed, the presence of necrosis was found to be more likely in
cases with large tumours (P¼0.004), higher tumour status
(P¼0.023), presence of nodal metastasis (P¼0.030), presence of
distant metastasis (P¼0.049), higher TNM stage (P¼0.009),
poorer tumour differentiation (Po0.0001), and more frequent
venous invasion (P¼0.0002).
Prognostic significance of the histopathological valuables
Survival analysis demonstrated an association between the
presence of necrosis and shorter DFS (Po0.0001; HR¼2.007;
95% CI: 1.531–2.630) and DSS (Po0.0001; HR¼2.196; 95% CI:
Massive necrosis
Micronecrosis
Figure 1 Representative histology of massive necrosis (upper columns) and micronecrosis (lower columns). Arrows indicate necrotic area. Left, centre,
and right columns are in low ( 6.25), middle ( 20), and high magnification ( 100), respectively. High power view of histology in right columns
corresponds to the rectangle (solid line) in left or middle column. Middle power view of histology in centre columns corresponds to the rectangle (dotted
line) in left columns.
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s1.659–2.905) (Figure 4). A similar association was found in
patients with PDC at each TNM stages (Figure 4).
The average survival periods for patients having PDC with and
without necrosis were 24.62±1.42 months and 47.36±2.75
months, respectively. One-year survival rates for patients having
PDC with and without necrosis were 63.3±3.3% and 89.1±2.9%,
respectively; the 2-year rates were 36.2±3.4% and 69.0±4.3%, and
the 5-year rates were 17.1±2.9% and 40.1±4.8%.
Multivariate Cox regression analysis showed that necrosis
(Po0.0001; HR¼1.853; 95% CI: 1.407–2.440), metastatic status,
Massive necrosis
Micronecrosis
Figure 2 Hypoxia is reflected by the presence of massive necrosis or micronecrosis. Expression of CAIX is immunohistochemically detectable in both
cancer cells and stromal cells within or around areas of massive necrosis (upper columns) and micronecrosis (lower columns). Carbonic anhydrase IX is
expressed in plasma membrane. Arrows indicate necrotic area. Low power view (left columns) and high power view (right columns).
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Figure 3 Kaplan–Meier survival curves showing the comparison of disease-free survival between high and low expression of CAIX (P-values obtained
from log-rank test) (left columns). Kaplan–Meier survival curves showing the comparison of disease-specific survival between high and low expression
of CAIX (P-values obtained from log-rank test) (right columns).
Prognostic marker of pancreatic cancer
N Hiraoka et al
1061
British Journal of Cancer (2010) 103(7), 1057–1065 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
slymphatic invasion, venous invasion, and intrapancreatic neural
invasion were independent predictors of DFS, and that necrosis
(Po0.0001; HR¼2.238; 95% CI: 1.686–2.971), metastatic status,
margin status, lymphatic invasion, and intrapancreatic neural
invasion were independent predictors of DSS (Table 2).
When massive necrosis and micronecrosis were separated
as distinct variables, univariate survival analysis demonstrated
an association between the presence of massive necrosis and
shorter DFS (Po0.0001) and DSS (Po0.0001), and between the
presence of micronecrosis and shorter DFS (P¼0.004) and DSS
(P¼0.001) (Supplementary Table 2). Multivariate Cox regression
analysis showed that massive necrosis (P¼0.0006) and micro-
necrosis (P¼0.0004) were independent predictors of shorter
DFS and that massive necrosis (Po0.0001) and micro-
necrosis (Po0.0001) were independent predictors of shorter DSS
(Supplementary Table 2).
Reproducibility of necrosis identification by independent
observers
Interobserver agreement (reproducibility) regarding the identifi-
cation of necrosis among the five independent observers who
reviewed the 51 slides blindly had a k-value of 0.87. On the other
hand, the corresponding k-values for grading (0–3) of lymphatic,
venous, and neural invasion were 0.11, 0.11, and 0.31, respectively.
According to the widely used statistical chart that grades the
strength of agreement (Fleiss, 1971; Landis and Koch, 1977) into
6 categories (poor (k-value, o0.00), slight (0.00–0.20), fair
(0.21–0.40), moderate (0.41–0.60), substantial (0.61–0.80), and
almost perfect (0.81–1.00)), the agreement for identification of
necrosis and the grading for lymphatic, venous, and neural inva-
sion were categorized as ‘almost perfect’, ‘slight’, ‘slight’, and ‘fair’,
respectively. When the grades for lymphatic, venous, and neural
Total
P <0.0001
Total
P <0.0001
Stages IA, IB, and IIA
P = 0.016
Stages IA, IB, and IIA
P = 0.025
Stage IIB
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Figure 4 Kaplan–Meier survival curves showing a comparison of disease-free survival between cases in which histological necrosis was present and absent
(P-values obtained by log-rank test) (left columns). Kaplan–Meier survival curves showing a comparison of disease-specific survival between cases, in which
histological necrosis was present and absent (P-values obtained by log-rank test) (right columns).
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sinvasion were combined into two categories (grades 0 and 1 and
grades 2 and 3) as used in the survival analysis, the k-values for
lymphatic, venous, and neural invasion were 0.55 (moderate),
0.62 (substantial), and 0.62 (substantial), respectively.
Survival analysis was performed using the data for necrosis
identification by the five independent observers, and this
yielded similar results, that is, patients having PDC with necrosis
showed significantly shorter survival. P-values calculated for
each of these analyses were 0.0004, 0.0005, 0.002, 0.005, 0.006,
and 0.008 for DFS, and 0.0001, 0.0004, 0.003, 0.005, 0.005, and
0.008 for DSS.
DISCUSSION
Pancreatic ductal carcinoma is one of the most aggressive cancers,
with almost equivalent incidence and mortality rates. Several
histopathological prognostic variables for patients with PDC have
been reported (Trede et al, 1990; Yeo et al, 1995; Luttges et al,
2000; Sohn et al, 2000; Lim et al, 2003; Takai et al, 2003; Adsay
et al, 2005; Mitsunaga et al, 2005, 2007; Shimada et al, 2006;
Schnelldorfer et al, 2008). These are sometimes controversial and
complex, and some have problems related to interobserver
reproducibility. We need prognostic indicators being simpler,
more reproducible, and accurate.
In this study, we reviewed the histopathological findings in 348
cases of PDC in comparison with the corresponding clinico-
pathological information, and obtained several histopathological
prognosticators of both DFS and DSS for patients with PDC
by univariate survival analyses employing histological necrosis,
tumour size, tumour status, node status, metastatic status,
margin status, nerve plexus invasion, and lymphatic, venous, and
intrapancreatic neural invasion as variables. Multivariate survival
analyses revealed that histological necrosis was an independent
predictive factor for both shorter DFS (Po0.0001) and shorter DSS
(Po0.0001) of PDC patients (Table 2). In addition, metastatic
status, lymphatic invasion, venous invasion, and intrapancreatic
neural invasion were factors that were independently predictive of
shorter DFS, whereas metastatic status, margin status, lymphatic
invasion, and intrapancreatic neural invasion were factors
independently predictive of shorter DSS (Table 2). Necrosis was
also able to predict patient outcome in populations at stage IIB,
into which the majority of resectable PDCs were stratified
(Figure 4). Furthermore, the reproducibility of necrosis identifica-
tion was found to be ‘almost perfect’ (k-value, 0.87) when the
51 slides of PDC were assessed by five independent observers.
In contrast, the reproducibility of the systems of grading for
lymphatic, venous, and neural invasion was low with low k-values.
Moreover, these five independent observers all provided the same
result, that is, that patients having PDC with necrosis showed
Table 2 Univariate and multivariate analyses of prognostic factors associated with disease-free survival in patients with ductal carcinoma of the
pancreas (n¼348)
Univariate analysis Multivariate analysis
Variables HR (95% CI) P-value HR (95% CI) P-value
Age (X60 years/o60 years) 1.159 (0.895–1.501) 0.263
Gender (male/female) 0.987 (0.764–1.274) 0.919
Localisation (pancreas head/body or tail) 0.865 (0.657–1.140) 0.304
Tumour size (X30mm/o30mm) 1.789 (1.306–2.450) 0.0003
Pathologic tumour status (T1+T2/T3) 3.863 (1.235–12.1) 0.020
Pathologic node status (N0/N1) 2.028 (1.416–2.906) 0.0001
Pathologic metastasis status (M0/M1) 2.258 (1.550–3.289) o0.0001 2.042 (1.387–3.006) 0.0003
Histological grade (W/D/M/D, P/D)
a 1.507 (1.122–2.025) 0.006
Tumour margin status (negative/positive) 1.470 (1.121–1.929) 0.005
PL (absence/presence)
a 1.560 (1.182–2.060) 0.002
Lymphatic invasion (0, 1/2, 3)
a 2.040 (1.513–2.751) o0.0001 1.475 (1.068–2.038) 0.018
Venous invasion (0, 1/2, 3)
a 1.985 (1.508–2.614) o0.0001 1.474 (1.097–1.980) 0.010
Intrapancreatic neural invasion (0, 1/2, 3)
a 1.655 (1.269–2.157) 0.0002 1.506 (1.145–1.981) 0.003
Histological necrosis (absence/presence) 2.007 (1.531–2.630) o0.0001 1.853 (1.407–2.440) o0.0001
Univariate and multivariate analyses of prognostic factors associated with disease-specific survival in patients with ductal carcinoma of the pancreas (n¼348)
Univariate analysis Multivariate analysis
Variables HR (95% CI) P-value HR (95% CI) P-value
Age (X60 years/o60 years) 1.054 (0.811–1.371) 0.692
Gender (male/female) 0.935 (0.721–1.213) 0.615
Localisation (pancreas head/body or tail) 0.829 (0.628–1.096) 0.189
Tumour size (X30mm/o30mm) 1.890 (1.371–2.605) 0.0001
Pathologic tumour status (T1+T2/T3) 6.333 (1.572–25.5) 0.009
Pathologic node status (N0/N1) 2.024 (1.406–2.915) 0.0002
Pathologic metastasis status (M0/M1) 2.199 (1.509–3.204) o0.0001 1.839 (1.252–2.700) 0.002
Histological grade (W/D/M/D, P/D)
a 1.611 (1.193–2.176) 0.002
Tumour margin status (negative/positive) 1.555 (1.183–2.043) 0.002 1.379 (1.038–1.833) 0.027
PL (absence/presence)
a 1.690 (1.267–2.253) 0.0004
Lymphatic invasion (0, 1/2, 3)
a 2.409 (1.762–3.293) o0.0001 1.992 (1.440–2.757) o0.0001
Venous invasion (0, 1/2, 3)
a 1.968 (1.486–2.607) o0.0001
Intrapancreatic neural invasion (0, 1/2, 3)
a 1.709 (1.305–2.238) o0.0001 1.443 (1.087–1.915) 0.011
Histological necrosis (absence/presence) 2.196 (1.659–2.905) o0.0001 2.238 (1.686–2.971) o0.0001
Abbreviations: CI¼confidence interval; HR¼hazards ratio; M/D¼moderately differentiated adenocarcinoma; P/D¼poorly differentaited adenocarcinoma; PL¼nerve plexus
invasion; W/D¼well-differentiated adenocarcinoma.
aClassified according to the classification of pancreatic carcinoma of Japan Pancreas Society
Prognostic marker of pancreatic cancer
N Hiraoka et al
1063
British Journal of Cancer (2010) 103(7), 1057–1065 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
ssignificantly shorter survival in terms of both DFS and DSS. These
findings indicate that histological necrosis is a simple, accurate,
and reproducible predictor of postoperative outcome for PDC
patients.
Histological necrosis was found in 223 (64.1%) out of 348 cases
of PDC. We defined necrosis as covering both massive necrosis
and micronecrosis, the latter being often evident in PDCs, although
not noted previously or being hidden as smaller foci (Couvelard
et al, 2005; Mitsunaga et al, 2005). The expression of CAIX
(Figure 2) and HIF-1a (data now shown) in and around the
necrotic areas was detected immunohistochemically, together with
that the presence of necrosis was significantly correlated with
expression of CAIX (Table 1), indicating that both patterns of
necrosis were closely related to hypoxia. Hasebe’s group reported
that necrosis was an independent prognostic factor in both DFS
and DSS when they investigated histopathological findings in
101 PDC patients (Nakatsura et al, 1997; Mitsunaga et al, 2005).
Couvelard et al (2005) reported that necrosis was associated with
poorer DSS in univariate analysis, and also showed that necrosis
was significantly associated with CAIX expression. Only 30–40%
of PDC cases had necrosis in those studies, whereas 60–80% of
PDCs had hypoxia, as necrosis was defined roughly by these two
groups as massive necrosis only.
When massive necrosis and micronecrosis were separated as
distinct variables, univariate and multivariate survival analyses
demonstrated that both types of necrosis were significantly
associated with shorter DFS and DSS (Supplementary Table 2).
Massive necrosis and micronecrosis was detected in 27.9 and
43.4% (overlapped 7.2%) of PDCs in our series, respectively. These
findings suggest that the presence of necrosis, even when the lesion
is small, is closely associated with patient outcome, probably
because the presence of necrosis represents a hypoxia-associated
aggressive tumour phenotype. In fact, in this series, the presence of
necrosis was significantly correlated with a large tumour size,
higher T factor, presence of nodal and distant metastasis, higher
TNM stage, more severe venous invasion, and a higher tumour
histological grade (Table 1), suggesting that necrosis is positively
correlated with tumour growth, invasion, and angiogenesis, that is,
an aggressive phenotype.
Hypoxia is a characteristic of invasive cancers that can lead to
the development of an aggressive phenotype through a mechanism
mediated mainly by HIF-1a, which includes cell immortalisation
and dedifferentiation, pH regulation, autocrine growth/survival,
angiogenesis, invasion/metastasis, and resistance to chemotherapy
(Semenza, 2006, 2009; Grothey and Galanis, 2009). In fact, the
presence of hypoxic foci with expression of CAIX was an
independent worse prognostic factor for PDC patients (Supple-
mentary Table 1) that we demonstrated at first time using
large series of cases. Recently, HIF-1 targeting therapy and anti-
angiogenesis therapy have been reported to yield promising anti-
cancer effects (Sessa et al, 2008; Grothey and Galanis, 2009;
Semenza, 2009). It is suggested that evaluation of histological
necrosis would be useful not only for decision making about
postoperative clinical management, but also for stratifying patients
for clinical trials aimed at evaluating HIF-1 targeting or anti-
angiogenesis therapies.
In conclusion, we reviewed the histopathological findings in 348
PDCs for which the presence of necrosis was redefined, and found
that histological necrosis was an independent predictor of shorter
DFS and DSS for the affected patients. Interobserver reproduci-
bility for the detection of necrosis was assessed as ‘almost perfect’
when 51 slides of PDC were reviewed by five independent
observers. These findings indicate that histological necrosis is a
simple, accurate, and reproducible predictor of postoperative
outcome in PDC patients.
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